Literature DB >> 25178895

Educational paper: therapy of infantile haemangioma--history and current state (part II).

Sherief R Janmohamed1, Gerard C Madern, Peter C J de Laat, Arnold P Oranje.   

Abstract

UNLABELLED: Infantile haemangioma (IH) is the most frequent tumour of infancy. Although it is benign and self-limiting, severe complications can arise due to localisation and fast tumour growth. Also, IHs leave scars after regression in more than half of the cases. Management and therapy of IH have changed greatly after 2008. This update provides an overview of the older therapy options before 2008, which mainly consisted of the administration of corticosteroids, and discusses the modern management with new therapy options such as β-blockers (both systemically and topically).
CONCLUSION: β-blockers are promising and are currently preferred above corticosteroids, but β-blockers still do not give a definitive treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25178895     DOI: 10.1007/s00431-014-2404-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  63 in total

1.  Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS).

Authors:  S R Janmohamed; F B de Waard-van der Spek; G C Madern; P C J de Laat; W C J Hop; A P Oranje
Journal:  Clin Exp Dermatol       Date:  2011-06-10       Impact factor: 3.470

Review 2.  Current treatment practices in the management of cutaneous haemangioma.

Authors:  Yuin-Chew Chan
Journal:  Expert Opin Pharmacother       Date:  2004-09       Impact factor: 3.889

Review 3.  Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.

Authors:  Shoshana Greenberger; Joyce Bischoff
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

4.  Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis.

Authors:  S Pérez-Valle; M Peinador; P Herraiz; P Saénz; G Montoliu; M Vento
Journal:  Acta Paediatr       Date:  2010-02       Impact factor: 2.299

5.  Complications of systemic corticosteroid therapy for problematic hemangioma.

Authors:  L M Boon; D M MacDonald; J B Mulliken
Journal:  Plast Reconstr Surg       Date:  1999-11       Impact factor: 4.730

6.  Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma.

Authors:  Mark E Kleinman; Matthew R Greives; Samara S Churgin; Keith M Blechman; Eric I Chang; Daniel J Ceradini; Oren M Tepper; Geoffrey C Gurtner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-09-13       Impact factor: 8.311

7.  Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF.

Authors:  Damian Medici; Bjorn R Olsen
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

Review 8.  Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature.

Authors:  John Nguyen; Aaron Fay
Journal:  Semin Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.975

Review 9.  Infantile hemangioma: challenges, new insights, and therapeutic promise.

Authors:  Eileen Boye; Masatoshi Jinnin; Bjorn R Olsen
Journal:  J Craniofac Surg       Date:  2009-03       Impact factor: 1.046

10.  Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis.

Authors:  Jina J Y Kum; Zia A Khan
Journal:  Pediatr Res       Date:  2013-12-02       Impact factor: 3.756

View more
  3 in total

Review 1.  Educational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I).

Authors:  Sherief R Janmohamed; Gerard C Madern; Peter C J de Laat; Arnold P Oranje
Journal:  Eur J Pediatr       Date:  2014-08-26       Impact factor: 3.183

2.  Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma.

Authors:  Ling Zhang; Hai Wei Wu; Weien Yuan; Jia Wei Zheng
Journal:  Cancer Manag Res       Date:  2017-07-07       Impact factor: 3.989

Review 3.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.